Clinical trials
Terminated Communicable Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 22 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| RVAC Medicines (US), Inc. | 2 |
| 101 Therapeutics | 1 |
| Brigham and Women's Hospital | 1 |
| Bugworks Research Inc. | 1 |
| Central Hospital, Nancy, France | 1 |
| Cytheris SA | 1 |
| Fairview University Medical Center | 1 |
| Fundació Institut Germans Trias i Pujol | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Communicable Diseases | 22 |
| COVID-19 | 4 |
| Bacterial Infections | 2 |
| Immune System Diseases | 2 |
| Rare Diseases | 2 |
| Tuberculosis | 2 |
| Chediak-Higashi Syndrome | 1 |
| Clostridium Infections | 1 |
| Common Variable Immunodeficiency | 1 |
| Cytokine Release Syndrome | 1 |
Trials
Showing 26 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.